Dr. Kostas Alevizopoulos joined Ventac Partners in August 2007. He brings more than fifteen years of corporate expertise in the development and commercialization of therapeutic, diagnostic, medical devices and OTC products in the biomedical sector. His personal track record includes management of more than 100 international preclinical and clinical projects on behalf of several companies or academic institutions and development and regulatory approvals of >5 heath products in various countries or regions.
Since 2010, Dr. Alevizopoulos serves as the Chief Executive Officer of APIM Therapeutics AS, a venture-capital financed oncology biotech company (Norway). He is also a co-founder of Zestagen (Switzerland), CASiGEN Pharma (Hong Kong), PharmaCellion (UK) and of the Hellenic Biotechnology Cluster (Greece). Important positions in his curriculum outside Ventac Partners include: Chief Scientific Officer of Gerolymatos International SA (GR), Chief Executive Officer of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R & D of Apotech Corporation (CH).
Dr. Alevizopoulos received his Biology degree from the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Plough Research Institute (USA) specializing in preclinical oncology research. Overall he has published more than 25 peer-reviewed publications and he is a co-inventor in several patent families. Dr. Alevizopoulos is trained in European Patent Law (Robert Schuman University of Strasbourg, France).